PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Sotagliflozin - Diabetes Mellitus

PAD Profile : Sotagliflozin - Diabetes Mellitus

Keywords :
NICE, SGLT2s, SGLT2 inhibitors, sodium glucose co-transporter 2 inhibitors, diabetic ketoacidosis, DKA, type 1 diabetes

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Important
Formulations :
  • Tablets
Important Information :
Sotagliflozin is not yet available in the NHS. The NICE TA622 will not be implemented until the product is available. Place in therapy will also be determined at this time.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
NICE Technology Appraisal
NICE TA622 - Sotagliflozin with insulin for treating type 1 diabetes - February 2020.pdf

Committee Recommendations

Date
Committee Name
Narrative
04 March 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey & North West Sussex Area Prescribing Committee will not move to implement this guidance until this product has been launched in the UK. Please see the statement from NICE in relation to implementation timeframes for this guidance:

Section 7(6) of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires clinical commissioning groups, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this appraisal within 3 months of its date of publication. However, the company has informed NICE that sotagliflozin is not yet available in the NHS. Therefore, the period during which the NHS in England has to comply with the recommendations has been extended to within 3 months of the commercial launch of sotogliflozin in England. This extension is made under section 7(5b) of the regulations

Associated BNF Codes

06. Endocrine System
06.01.02. Antidiabetic drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More